[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1860
86. Karmazin A, Moore WV, Popovic J, Jacobson JD: The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function. J Pediatr Endocrinol Metab; 2005 Mar;18(3):285-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function.
  • Low-dose ACTH stimulation tests were performed to ascertain the effect of letrozole on adrenal gland function.
  • 1) letrozole decelerates skeletal maturation, resulting in significant increases in predicted adult height, and 2) letrozole causes mild adrenal suppression.
  • [MeSH-major] Adrenal Glands / drug effects. Adrenal Glands / physiology. Aromatase Inhibitors / adverse effects. Aromatase Inhibitors / pharmacology. Body Height. Bone Development / drug effects. Bone and Bones / drug effects. Growth Disorders / drug therapy. Nitriles / adverse effects. Nitriles / pharmacology. Triazoles / adverse effects. Triazoles / pharmacology

  • MedlinePlus Health Information. consumer health - Growth Disorders.
  • Hazardous Substances Data Bank. LETROZOLE .
  • Hazardous Substances Data Bank. Corticotropin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15813607.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


87. Dunning KK, Wudhikarn K, Safo AO, Holman CJ, McKenna RW, Pambuccian SE: Adrenal extranodal NK/T-cell lymphoma diagnosed by fine-needle aspiration and cerebrospinal fluid cytology and immunophenotyping: a case report. Diagn Cytopathol; 2009 Sep;37(9):686-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal extranodal NK/T-cell lymphoma diagnosed by fine-needle aspiration and cerebrospinal fluid cytology and immunophenotyping: a case report.
  • The cytologic findings of an extranodal NK/T-cell lymphoma (NKTCL) presenting as a large adrenal mass with leptomeningeal involvement diagnosed by CT-guided fine-needle aspiration and cerebrospinal fluid (CSF) cytology are described.
  • Magnetic resonance imaging showed leptomeningeal enhancement surrounding the conus medullaris and cauda equine, and a subsequent PET/CT demonstrated a large right adrenal gland mass.
  • Fine-needle aspiration of the adrenal mass showed occasional large pleomorphic cells with prominent nucleoli, moderate amounts of cytoplasm, and rare large cells with sparse cytoplasmic granules admixed with numerous small lymphocytes.
  • The cytologic findings of the neoplastic cells and the extensive panel of immunoperoxidase stains allowed the diagnosis of NKTCL, which was confirmed by the subsequent flow-cytometric immunophenotyping performed on the CSF.
  • This is, to the best of our knowledge, the first case of NKTCL diagnosed by FNA of the adrenal gland and by CSF cytology.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Killer Cells, Natural / pathology. Lymphoma, T-Cell / cerebrospinal fluid. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Fatal Outcome. Flow Cytometry. Humans. Immunohistochemistry. Immunophenotyping. Magnetic Resonance Imaging. Male. Meningeal Carcinomatosis / pathology. Positron-Emission Tomography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Wiley-Liss, Inc.
  • (PMID = 19373919.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


88. Ruffoli R, Carpi A, Giambelluca MA, Grasso L, Scavuzzo MC, Giannessi F F: Diazepam administration prevents testosterone decrease and lipofuscin accumulation in testis of mouse exposed to chronic noise stress. Andrologia; 2006 Oct;38(5):159-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diazepam may inhibit lipofuscinogenesis in liver and prevent the noise-induced reduction of the steroidogenesis in the adrenal gland.

  • MedlinePlus Health Information. consumer health - Noise.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIAZEPAM .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16961568.001).
  • [ISSN] 0303-4569
  • [Journal-full-title] Andrologia
  • [ISO-abbreviation] Andrologia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Lipofuscin; 3XMK78S47O / Testosterone; Q3JTX2Q7TU / Diazepam
  •  go-up   go-down


89. Vogl TJ, Zangos S, Eichler K, Balzer JO, Jacob U, Keilhauer R, Bauer RW: [Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases]. Rofo; 2007 Nov;179(11):1174-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate local transarterial chemoperfusion (TACP) of therapy-resistant, locally recurrent malignant tumors and lymph node metastases in the pelvis with respect to clinical response, tumor response and survival.
  • Depending on the tumor location and vascularization, a fluoroscopy catheter was placed either in the abdominal aorta or internal pelvic artery.
  • The tumor size was measured using CT or MRI.
  • In the case of clinical and radiological progression, therapy was stopped and the patient was referred to the hospital's tumor board.
  • Tumor-related pain, bleeding, restricted mobility of the lower extremities, incontinence, urinary tract obstruction, and constipation were reduced in 9/17, 5/6, 3/3, 1/3, 2/5, and 1/3 of cases (clinical response rate: 54%).
  • Radiologically, 4/24 (17%) patients showed PR, 12/24 (50%) SD, and 8/24 (34%) PD (tumor control (PR+SD): 67% of cases).
  • Tumor response (median survival since first TACP) was as follows: colorectal: 2 PR, 7 SD, 2 PD (11.5 months), ovarian: 1 SD, 2 PD (8.5 mon), cervical: 1 PR, 1 SD (6 mon), breast: 2 SD (6 mon), gastric: 1 PD (11 mon), adrenal gland: 1 PD (12 mon), anal: 1 PD (10 mon), prostate: 1 PD (20 mon), Gartner's duct: 1 PR (20 mon), renal cell carcinoma: 1 SD (10 mon).
  • CONCLUSION: Since tumor-related complaints were improved in 54% of the cases and control of tumor growth (PR+SD) was achieved in 67% of the cases, TACP for recurrent pelvic malignancies should be considered as a palliative oncological treatment option.
  • [MeSH-major] Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Arteries. Drug Resistance, Neoplasm. Female. Humans. Injections, Intra-Arterial / adverse effects. Middle Aged. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Perfusion / adverse effects. Retrospective Studies. Survival Analysis

  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805998.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin
  •  go-up   go-down


90. Singh KP, Roy D: SKCG-1: a new candidate growth regulatory gene at chromosome 11q23.2 in human sporadic Wilms tumours. Br J Cancer; 2006 May 22;94(10):1524-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using arbitrary primed-PCR (AP-PCR), we have identified a novel genetic alteration located at chromosome 11q23.2 and this genetic alteration was common in 38% of the human Wilms tumour samples analysed.
  • The transcript of SKCG-1 was abundantly present in brain, kidney, liver, testis, salivary gland, foetal brain, foetal liver, whereas relatively lower expression in heart, stomach, prostate and no expression in spleen, colon, lung, small intestine, muscle, adrenal gland, uterus, skin, PBL, and bone marrow was detected.
  • Thus, the findings of this study revealed (i) SKCG-1, a new gene located at 11q23.2 and harbouring genetic alteration in Wilms tumours, (ii) the presence of SKCG-1 gene transcripts in various human normal tissues and its lower expression or absence in Wilms and breast tumours indicate that it may be associated with tumour growth suppressor activity, (iii) the presence of an open reading frame in the cDNA sequence of SKCG-1 indicates that it has potential to encode a protein, (iv) increased cell growth by silencing this gene in HEK293 cells further supports a potential role of this gene in growth of kidney epithelial cells.
  • Our findings suggest that SKCG-1 may have a tumour suppressor role, and implicate genetic alteration in this gene as a potential oncogenic pathway and therapeutic target in kidney and breast cancer.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 1999 Jan;14(1):235-41 [9987668.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):17079-85 [9642273.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5975-9 [10606244.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):189-93 [11125087.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):393-8 [11159177.001]
  • [Cites] Gene. 2001 May 16;269(1-2):33-43 [11376935.001]
  • [Cites] Gene. 2001 Aug 8;273(2):141-61 [11595161.001]
  • [Cites] Hum Genet. 1981;57(3):231-46 [6265341.001]
  • [Cites] Hum Genet. 1988 Dec;81(1):41-8 [2848758.001]
  • [Cites] Am J Hum Genet. 1989 May;44(5):711-9 [2539717.001]
  • [Cites] Cell. 1990 Feb 9;60(3):509-20 [2154335.001]
  • [Cites] Nature. 1990 Feb 22;343(6260):774-8 [2154702.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3094-8 [1317258.001]
  • [Cites] Methods Enzymol. 1993;218:340-56 [7685466.001]
  • [Cites] Cytogenet Cell Genet. 1994;65(3):206-18 [8222762.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2331-3 [8162576.001]
  • [Cites] Nat Genet. 1994 May;7(1):91-7 [8075648.001]
  • [Cites] Mol Cell Biol. 1994 Nov;14(11):7095-104 [7523860.001]
  • [Cites] EMBO J. 1994 Nov 1;13(21):5099-112 [7957074.001]
  • [Cites] Genomics. 1995 Mar 1;26(1):134-7 [7782072.001]
  • [Cites] Genomics. 1995 Jun 10;27(3):497-501 [7558032.001]
  • [Cites] FEBS Lett. 1996 May 20;386(2-3):156-60 [8647271.001]
  • [Cites] Mamm Genome. 1996 Aug;7(8):563-74 [8679005.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11837-41 [8876224.001]
  • [Cites] Int J Oncol. 1999 Apr;14(4):753-8 [10087325.001]
  • (PMID = 16622458.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Databank-accession-numbers] GENBANK/ AY662656
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES010851; United States / NCI NIH HHS / CA / CA 4788; United States / NIEHS NIH HHS / ES / ES 10851
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Membrane Proteins; 0 / SKCG-1 protein, human
  • [Other-IDs] NLM/ PMC2361289
  •  go-up   go-down


91. Hesketh SA, Leggett JD, Jessop DS: Chronic citalopram treatment does not sensitize the adrenal gland to ACTH (1-24) in rats. J Psychopharmacol; 2007 Nov;21(8):885-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic citalopram treatment does not sensitize the adrenal gland to ACTH (1-24) in rats.
  • Thus we proposed the hypothesis that the corticosterone response to restraint in citalopram-treated rats was maintained due to increased adrenal sensitivity to lower ACTH levels.
  • Therefore we conclude that, under these experimental conditions, citalopram does not appear to sensitize the rodent adrenal gland to ACTH, and that other mechanisms may be responsible for the ACTH/corticosterone disconnection.
  • [MeSH-major] Adrenal Glands / drug effects. Citalopram / pharmacology. Cosyntropin / pharmacology. Serotonin Uptake Inhibitors / pharmacology

  • Hazardous Substances Data Bank. Cosyntropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17715205.001).
  • [ISSN] 0269-8811
  • [Journal-full-title] Journal of psychopharmacology (Oxford, England)
  • [ISO-abbreviation] J. Psychopharmacol. (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Serotonin Uptake Inhibitors; 0DHU5B8D6V / Citalopram; 16960-16-0 / Cosyntropin; W980KJ009P / Corticosterone
  •  go-up   go-down


92. Suzuki S, Uchida D, Koide H, Suyama K, Shibata T, Yoshida T, Tanaka T, Noguchi Y, Saito Y, Tatsuno I: A possible association between aldosterone response to vasopressin and circadian change of aldosterone in the patients with aldosterone-producing adenoma. Peptides; 2008 Dec;29(12):2225-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vasopressin was reported to stimulate secretion of both cortisol and aldosterone through eutopic V1a receptors in adrenal gland.
  • Recently, adrenal hyper-responsiveness of plasma cortisol to vasopressin with eutopic overexpession of V1a receptors has been reported in Cushing's syndrome, such as a majority of cases of ACTH-independent macronodular adrenal hyperplasia and some cases of Cushing's adenomas.
  • Vasopressin-loading test was performed in 10 patients with aldosterone-producing adenoma, and in 16 patients with non-functioning adrenal tumors.
  • The roles of the aldosterone response to vasopressin were analyzed in terms of hormonal secretion and the expression of V1a receptor mRNA on the operated adrenal gland in aldosterone-producing adenoma.
  • We found that (1) a varying aldosterone response to vasopressin was observed, (2) absolute response of plasma aldosterone in aldosterone-producing adenoma was significantly higher than that in non-functioning tumor, (3) aldosterone response rate to vasopressin was significantly and negatively correlated with the decline rate (%) in plasma aldosterone from morning to evening in aldosterone-producing adenoma, (4) V1a receptor mRNA was expressed at various values in aldosterone-producing adenoma, and (5) surgical removal of aldosterone-producing adenoma eliminated the aldosterone response to vasopressin observed in patients with aldosterone-producing adenoma.
  • [MeSH-major] Adenoma / metabolism. Aldosterone / blood. Circadian Rhythm. Pituitary Neoplasms / metabolism. Vasopressins / pharmacology
  • [MeSH-minor] Adrenal Glands / metabolism. Aged. Cushing Syndrome / metabolism. Female. Humans. Male. Middle Aged. Prospective Studies. RNA, Messenger / metabolism. Receptors, Vasopressin / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. VASOPRESSIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838094.001).
  • [ISSN] 0196-9781
  • [Journal-full-title] Peptides
  • [ISO-abbreviation] Peptides
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Vasopressin; 11000-17-2 / Vasopressins; 4964P6T9RB / Aldosterone
  •  go-up   go-down


93. Ramer JC, Benson KG, Morrisey JK, O'Brien RT, Paul-Murphy J: Effects of melatonin administration on the clinical course of adrenocortical disease in domestic ferrets. J Am Vet Med Assoc; 2006 Dec 1;229(11):1743-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the effect of oral administration of melatonin on clinical signs, tumor size, and serum steroid hormone concentrations in ferrets with adrenocortical disease.
  • At 4-month intervals, a complete physical examination; abdominal ultrasonographic examination (including adrenal gland measurement); CBC; serum biochemical analyses; and assessment of serum estradiol, androstenedione, and 17alpha-hydroxyprogesterone concentrations were performed.
  • Mean width of the abnormally large adrenal glands was significantly increased after the 12-month treatment period.
  • Oral administration of melatonin did not decrease adrenal gland tumor growth in treated ferrets.
  • [MeSH-major] Adrenal Cortex Diseases / veterinary. Adrenal Cortex Neoplasms / veterinary. Ferrets. Melatonin / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELATONIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17144819.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; JL5DK93RCL / Melatonin
  •  go-up   go-down


9
Advertisement
4. Libè R, Fratticci A, Bertherat J: Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer; 2007 Mar;14(1):13-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adrenocortical cancer (ACC) is a rare tumor with a poor prognosis.
  • By contrast, benign adrenocortical tumors are frequent, underlying the importance of a correct diagnosis of malignancy of such tumors.
  • ACC can be diagnosed by the investigation of endocrine signs of steroid excess, symptoms due to tumor growth or an adrenal incidentaloma.
  • Imaging by CT-scan or MRI shows a large heterogeneous tumor with a low fat content.
  • Careful pathological investigation with the assessment of the Weiss score is important for the diagnosis of malignancy.
  • Tumors localized to the adrenal gland (McFarlane stages 1 and 2) have a better outcome than invasive and metastatic tumors (stages 3 and 4).
  • Tumor removal by a specialized team is crucial for treatment and should always aim at complete removal.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenal Cortex Neoplasms / therapy
  • [MeSH-minor] Genes, Tumor Suppressor. Humans. Oncogenes / genetics


95. Rahmouni K, Sigmund CD, Haynes WG, Mark AL: Hypothalamic ERK mediates the anorectic and thermogenic sympathetic effects of leptin. Diabetes; 2009 Mar;58(3):536-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Blockade of ERK1/2 abolishes leptin-induced increases in sympathetic nerve traffic to thermogenic brown adipose tissue (BAT) but does not alter the stimulatory effects of leptin on sympathetic nerve activity to kidney, hindlimb, or adrenal gland.
  • In contrast, blockade of PI 3-kinase prevents leptin-induced sympathetic activation to kidney but not to BAT, hindlimb, or adrenal gland.
  • CONCLUSIONS: Our findings indicate that hypothalamic ERK plays a key role in the control of food intake, body weight, and thermogenic sympathetic outflow by leptin but does not participate in the cardiovascular and renal sympathetic actions of leptin.


96. Krishnam M, Tomasian A, Davies L, Littler J, Curtis J: CT-guided percutaneous transpulmonary adrenal biopsy - a technical note. Br J Radiol; 2008 Jul;81(967):e191-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT-guided percutaneous transpulmonary adrenal biopsy - a technical note.
  • CT-guided percutaneous adrenal biopsy is commonly performed using a posterior or trans-abdominal approach.
  • However, trans-abdominal access to the gland may not be technically feasible in some patients.
  • In our case, CT-guided transthoracic percutaneous biopsy of the adrenal gland was performed with technical success, identifying the tumour.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Adrenal Glands / pathology. Biopsy / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559898.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Matsushima K: Traumatic adrenal gland hematoma: FAST is an effective tool to screen. J Trauma; 2009 Sep;67(3):676
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Traumatic adrenal gland hematoma: FAST is an effective tool to screen.
  • [MeSH-major] Abdominal Injuries / ultrasonography. Adrenal Gland Diseases / ultrasonography. Hematoma / ultrasonography. Wounds, Nonpenetrating / ultrasonography

  • MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19741419.001).
  • [ISSN] 1529-8809
  • [Journal-full-title] The Journal of trauma
  • [ISO-abbreviation] J Trauma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Ludescher B, Najib A, Baar S, Machann J, Schick F, Buchkremer G, Claussen CD, Eschweiler GW: Increase of visceral fat and adrenal gland volume in women with depression: preliminary results of a morphometric MRI study. Int J Psychiatry Med; 2008;38(3):229-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increase of visceral fat and adrenal gland volume in women with depression: preliminary results of a morphometric MRI study.
  • OBJECTIVE: Depression is often accompanied by increased visceral adipose tissue (VAT), stress, enlarged adrenal glands, and an increased risk of cardiovascular disease.
  • VAT turn-over is regulated by adrenal stress hormones such as cortisol.
  • Aim of this study was to investigate the relationship between the adrenal volume as a marker for long-term stress and the volume fractions of several body fat compartments in healthy and depressive women.
  • Fat compartments (VAT, VAT in the upper abdomen, subcutaneous adipose tissue (SCAT), and adrenal volume) were measured by MRI.
  • There was a significant correlation of age and Body Mass Index (BMI) with the visceral adipose tissue volume and adrenal gland size.
  • CONCLUSIONS: The increase of adrenal volume and VAT and the correlation of BDI with VAT in the upper abdomen support the hypothesis of long-term production of stress hormones in depression.
  • [MeSH-major] Adrenal Glands / anatomy & histology. Depressive Disorder / epidemiology. Intra-Abdominal Fat / anatomy & histology. Magnetic Resonance Imaging
  • [MeSH-minor] Biomarkers. Body Fat Distribution. Body Mass Index. Comorbidity. Control Groups. Female. Humans. Hydrocortisone / physiology. Middle Aged. Obesity / diagnosis. Obesity / epidemiology. Organ Size. Personality Inventory. Stress, Psychological / diagnosis. Stress, Psychological / epidemiology. Subcutaneous Fat. Whole Body Imaging

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069569.001).
  • [ISSN] 0091-2174
  • [Journal-full-title] International journal of psychiatry in medicine
  • [ISO-abbreviation] Int J Psychiatry Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


99. Eto M, Hamaguchi M, Harano M, Yokomizo A, Tatsugami K, Naito S: Laparoscopic adrenalectomy for malignant tumors. Int J Urol; 2008 Apr;15(4):295-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The treatment of malignant adrenal tumors using laparoscopic surgery remains controversial.
  • We thus compared the perioperative outcome of the laparoscopic adrenalectomy for the treatment of malignant tumors with the outcome for benign tumors.
  • The median adrenal tumor size was 3 cm.
  • Seven patients had no evidence of a systemic metastatic disease, whereas two patients with a metastatic renal cell carcinoma had systemic metastatic disease at the time of the operation.
  • There was no significant difference between laparoscopic adrenalectomy for malignant and benign tumors.
  • CONCLUSIONS: Our results clearly indicate that a laparoscopic adrenalectomy for the treatment of a metastatic adrenal malignancy can be performed with an acceptable outcome as a minimally invasive method in carefully selected patients.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy. Carcinoma / surgery. Laparoscopy

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18380814.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


100. Clark HA, Snedeker SM: Critical evaluation of the cancer risk of dibromochloropropane (DBCP). J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2005;23(2):215-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results from long-term cancer bioassays in rodents show a statistically significant increase in the incidence of malignant and benign mammary gland tumors in female rats treated orally with DBCP compared to controls and some evidence of increased incidence of mammary fibroadenomas in DBCP low-dose treated female rats exposed by inhalation.
  • Rats exposed to DBCP by inhalation showed significant increases in tumors of the tunica vaginalis in males; tumors of the pharynx and adrenal gland in females; and tumors of the tongue, nasal turbinate and nasal cavity in both sexes compared to controls.
  • Male and female mice exposed to DBCP by inhalation experienced increased tumor incidence in the lungs and nasal cavity compared to controls.
  • [MeSH-major] Antinematodal Agents / toxicity. Neoplasms / chemically induced. Propane / analogs & derivatives

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROPANE .
  • Hazardous Substances Data Bank. 1,2-DIBROMO-3-CHLOROPROPANE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16291528.001).
  • [ISSN] 1059-0501
  • [Journal-full-title] Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews
  • [ISO-abbreviation] J Environ Sci Health C Environ Carcinog Ecotoxicol Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antinematodal Agents; 0 / Carcinogens; 0 / Environmental Pollutants; 96K0FD4803 / 1,2-dibromo-3-chloropropane; T75W9911L6 / Propane
  • [Number-of-references] 118
  •  go-up   go-down






Advertisement